Biotech Values

[DewDiligence]

>> yet another "featured presentation" for NUVO next week.<<

I just caught NUVO’s 11/1/04 CC about AMGN’s pulling out of the JV to develop Alfimeprase. Wouldn’t you know: NUVO’s CEO, Ted Love, referred to Mark Monane’s inane remark that AMGN’s pullout is good for NUVO because it gives them “a higher percentage” of the drug (#msg-4451713).

Perhaps even more confidence-shaking than AMGN’s pullout, at least for me, is that NUVO has elected to forego an SPA for the phase-3 program! I’m updating my NUVO sentiment from weak sell (#msg-4270154) to just plain sell.